Hemastatx

Hemastatx is a biotech company focused on developing therapies for severe bleeding disorders, particularly those related to von Willebrand Factor (VWF). Founded in 2025 as a spin-off from KU Leuven, the company builds on extensive research conducted at the Laboratory for Thrombosis Research. Hemastatx's lead program involves a first-in-class antibody therapy aimed at treating VWF-related bleeding disorders by targeting the mechanism behind bleeding. The company operates in the hematology market, serving patients with severe and underserved bleeding conditions. Hemastatx's business model revolves around leveraging scientific excellence and clinical innovation to create cutting-edge therapies. Revenue is likely generated through partnerships with pharmaceutical companies, investors, and other stakeholders interested in advancing hemostatic therapies. The company is committed to advancing its research and engaging with partners to bring its therapies to market.

Keywords: bleeding disorders, VWF, antibody therapy, hematology, KU Leuven, thrombosis, hemostasis, biotech, clinical innovation, plasma metalloprotease